Median survival of patients with CLL by IgVH gene mutation and CD38 status
. | . | IgVH status . | . | CD38 status . | . | ||
|---|---|---|---|---|---|---|---|
. | N . | Nonmutated, n . | Mutated, n . | More than 30% positive, n . | Less than 30% positive, n . | ||
| Damle et al7 | 47 | 9 | Not reached | 10 | Not reached | ||
| Hamblin et al8 | 84 | 9.8 | 24.4 | — | — | ||
| Hamblin et al43 | 61 | — | — | 8.8 | 24.4 | ||
| Hamblin et al38 | 145 | 9.1 | 24.4 | 9.1 | 24.4 | ||
| Oscier et al39 | 205 | 9.9 | 25.8 | ‡ | ‡ | ||
| Matrai et al41 | 40 | 9 | Not reached | 5 | 13 | ||
| Jelinek et a36 * | 66 | 5.7 | Not reached | 4.5 | Not reached | ||
| Del Poeta et al44 | 168 | — | — | 7.5 | Not reached | ||
| Durig et al48 † | 129 | — | — | 10 | Not reached | ||
| D'Arena et al49 | 61 | — | — | 7.5 | Not reached | ||
| Chevallier et al45 | 111 | — | — | 6.4 | Not reached | ||
| Krober et al35 | 325 | 6.6 | 12.7 | 6.3‡ | 9.5‡ | ||
| Lin et al40 § | 71 | 7.5 | Not reached | 7.5 | Not reached | ||
| Ibrahim et al46 | 218 | — | — | 2.9 | Not reached | ||
| Mainou-Fowler et al47 | 81 | — | — | 9.7 | Not reached | ||
| Tobin et al37 | 119 | 5.9 | 10.2 | — | — | ||
| Magnac et al23 | 38 | 7 | Not reached | — | — | ||
| Ghia et al50 ¶ | 108 | 15.3 | Not reached | 15.3 | Not reached | ||
. | . | IgVH status . | . | CD38 status . | . | ||
|---|---|---|---|---|---|---|---|
. | N . | Nonmutated, n . | Mutated, n . | More than 30% positive, n . | Less than 30% positive, n . | ||
| Damle et al7 | 47 | 9 | Not reached | 10 | Not reached | ||
| Hamblin et al8 | 84 | 9.8 | 24.4 | — | — | ||
| Hamblin et al43 | 61 | — | — | 8.8 | 24.4 | ||
| Hamblin et al38 | 145 | 9.1 | 24.4 | 9.1 | 24.4 | ||
| Oscier et al39 | 205 | 9.9 | 25.8 | ‡ | ‡ | ||
| Matrai et al41 | 40 | 9 | Not reached | 5 | 13 | ||
| Jelinek et a36 * | 66 | 5.7 | Not reached | 4.5 | Not reached | ||
| Del Poeta et al44 | 168 | — | — | 7.5 | Not reached | ||
| Durig et al48 † | 129 | — | — | 10 | Not reached | ||
| D'Arena et al49 | 61 | — | — | 7.5 | Not reached | ||
| Chevallier et al45 | 111 | — | — | 6.4 | Not reached | ||
| Krober et al35 | 325 | 6.6 | 12.7 | 6.3‡ | 9.5‡ | ||
| Lin et al40 § | 71 | 7.5 | Not reached | 7.5 | Not reached | ||
| Ibrahim et al46 | 218 | — | — | 2.9 | Not reached | ||
| Mainou-Fowler et al47 | 81 | — | — | 9.7 | Not reached | ||
| Tobin et al37 | 119 | 5.9 | 10.2 | — | — | ||
| Magnac et al23 | 38 | 7 | Not reached | — | — | ||
| Ghia et al50 ¶ | 108 | 15.3 | Not reached | 15.3 | Not reached | ||
— indicates not evaluated.
From time of enrollment on trial.
Used cutoff of 20% rather than 30% to determine CD38 positivity.
Nonsignificant difference between groups.
Used 3 cutoffs to classify IgVH gene mutation status (<2%, 2%-5%, >5%) data shown for less than 2% and more than 5%.
for IgVH analysis, N = 108; for CD38 analysis N = 148. Study reported 3 categories of CD38 status: CD38-, CD38+, and bimodal CD38 expression. Data presented for CD38- and CD38+ groups are based on 30% cutoff. Discussed in “Mutational status and CD38.”